Sibeprenlimab for IgA kidney disease after prior study
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies sibeprenlimab to see if it can improve IgA nephropathy, a kidney inflammation condition. You may be able to join if you finished a previous related Otsuka study without major safety problems and your doctor thinks you could benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You already finished one of two earlier Otsuka studies (and had no safety problems).
- You must be able to sign consent and follow the trial visits and treatment plan.
- If you had a major side effect from the study drug before, you likely cannot join.
- You must not be pregnant, and you must follow birth-control rules if you could become pregnant or if you’re a male who can father a pregnancy.
- You cannot have “nephrotic syndrome” with several specific lab and symptom findings (but isolated high protein alone may be allowed).
- You generally cannot have serious/unstable major medical problems, recent transplant history, or a severe allergic reaction to the drug ingredients.
- You cannot be taking strong immune-suppressing medicines around the start of the trial (except certain short or local steroid uses).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This trial tests a new drug, HS-10390, to see if it can help people with IgA nephropathy. You may qualify if you have the condition, are on stable blood pressure medication, and meet certain kidney function and lab criteria.
This trial tests a new drug called mezagitamab for adults with IgA nephropathy, a kidney condition. The study aims to see if this drug can help reduce protein in the urine and preserve kidney function. You may be eligible if your kidney function is above a certain level and your urine protein is high enough.
This study tests a drug called sibeprenlimab to see how it affects kidney tissue in people with IgA nephropathy (IgAN), a condition where antibodies build up in the kidneys. It may help protect your kidneys if your disease is still active.
This study tests a new medicine called sibeprenlimab for young people with IgA nephropathy, a kidney disease. The medicine may help reduce protein in the urine and protect kidney function.
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
Hear when a new Immunoglobulin A Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.